Results 91 to 100 of about 195,924 (307)

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

Сибирский онкологический журнал, 2018
More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable  tumors receive adjuvant endocrine therapy.
V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan, P. V. Krivorotko, V. G. Ivanov, E. K. Zhiltsova, R. M. Paltuev, L. M. Bershtein, T. Yu. Semiglazova, S. S. Yerechshenko, V. V. Klimenko, V. S. Apollonova, A. V. Komyahov, A. A. Bessonov   +13 more
doaj   +1 more source

Autophagy and urothelial carcinoma of the bladder: A review. [PDF]

, 2016
The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little change in bladder cancer mortality in the
Chandrasekar, Thenappan, Evans, Christopher P   +1 more
core   +2 more sources

NIPAL1 Drives a Metabolic‐Epigenetic Feedback Loop to Promote Lactate‐Mediated Immune Evasion in Esophageal Cancer

Advanced Science, EarlyView.
The study identifies a NIPAL1‐driven metabolic‐epigenetic circuit in esophageal squamous cell carcinoma that promotes glycolysis, lactate accumulation, and H3K18 histone lactylation, forming a self‐sustaining loop that suppresses CD8+ T cell immunity.
Ri‐Xin Chen, Xiao‐Dan Ma, Shui‐Dan Xu, Ao‐Tian Mo, Min‐Hua Deng, Jun‐Han Wu, Wei‐Tao Zhuang, Jin‐Ling Duan, Shu‐Huan Xie, Jin‐Long Lin, Peng Lin, Ji‐Ming Tang, Hai‐Yu Zhou, Xiao‐Song Ben, Gui‐Bin Qiao, Dan Xie   +15 more
wiley   +1 more source

Comparison of the safety and efficacy of different neoadjuvant therapy cycles for locally advanced gastric cancer: a retrospective propensity score-matched cohort study

World Journal of Surgical Oncology
Background For locally advanced gastric cancer (LAGC), neoadjuvant therapy prior to radical gastrectomy has been widely used. However, the treatment cycle and factors affecting the efficacy of neoadjuvant therapy are still unclear.
Zhihua Ren, Juan Tang, Haolin Xu, Shiyang Hou, Yiwen Wang, Zhenyu Hou, Hui Qu   +6 more
doaj   +1 more source

Comparison of neoadjuvant treatment and surgery first for resectable or borderline resectable pancreatic carcinoma: A systematic review and network meta-analysis of randomized controlled trials.

PLoS ONE
BackgroundCurrent treatment recommendations for resectable or borderline pancreatic carcinoma support upfront surgery and adjuvant therapy. However, neoadjuvant therapy (NT) seems to increase prognosis of pancreatic carcinoma and come to everyone's ...
Lu Huan, Fucai Yu, Ding Cao, Hantao Zhou, Maoling Qin, Yang Cao   +5 more
doaj   +1 more source

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. [PDF]

, 2019
We analyzed DCE-MR images from 132 women with locally advanced breast cancer from the I-SPY1 trial to evaluate changes of intra-tumor heterogeneity for augmenting early prediction of pathologic complete response (pCR) and recurrence-free survival (RFS ...
Cohen, Eric, Davatzikos, Christos, Hsieh, Meng-Kang, Hylton, Nola, Jahani, Nariman, Kontos, Despina, Newitt, David, Pantalone, Lauren, Weinstein, Susan P   +8 more
core   +1 more source

Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. [PDF]

, 2014
BackgroundSipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully understood.
Amling, Christopher L, Carroll, Peter, Chan, Stephen, Corman, John, Fong, Lawrence, Frohlich, Mark W, Lewis, Jera, Sheikh, Nadeem A, Simko, Jeffrey, Sims, Robert B, Small, Eric J, Stephenson, Robert A, Weinberg, Vivian   +12 more
core   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph, Ghosh, Paramita M, He, Wei, Hum, Nicholas R, Loots, Gabriela G, Martin, Kelly A, Pan, Chong-Xian, Sebastian, Aimy, Siddiqui, Salma   +8 more
core   +2 more sources